Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, BioRestorative Therapies Inc maintains a gross margin of 10.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -31432.30%, while the net margin is -25748.11%. These profitability ratios, combined with a Return on Equity (ROE) of -208.21%, provide a clear picture of how effectively BRTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BRTX competes directly with industry leaders such as AMIX and NDRA. With a market capitalization of $4.95M, it holds a leading position in the sector. When comparing efficiency, BRTX's gross margin of 10.42% stands against AMIX's N/A and NDRA's N/A. Such benchmarking helps identify whether BioRestorative Therapies Inc is trading at a premium or discount relative to its financial performance.
